Projects

Alzheimer’s disease is preceded by a long asymptomatic phase during which amyloid β (Aβ) deposition and tau aggregation occur before cognitive symptoms emerge. Understanding how these pathological changes affect brain connectivity is critical for early detection and intervention. This thesis examines functional connectivity alterations across biologically defined stages of AD using a multimodal approach integrating ...

Alzheimer’s disease (AD) is characterized by amyloid-beta (Ab) plaques, tau neurofibrillary tangles, synapse loss and neurodegeneration. However, the exact interplay between Ab and tau pathology and how their combination leads to synapse loss and neurodegeneration remains unclear. It is thought that Ab facilitates the trans-synaptic spread of tau across brain networks. Subsequently, tau is believed to cause the downstream synapse loss that ...

Alzheimer’s disease is a progressive neurodegenerative and the most common cause of dementia. Considering the Amyloid hypothesis, the tendency of beta-amyloid peptides to aggregate leads to the formation of toxic soluble oligomers, and insoluble fibrils and plaques, triggering a complex of biochemical and cellular responses; that lead later to neuroinflammation, loss of synapses, and neuronal necroptosis, and finally cognitive ...

With annually 9.9 million new cases worldwide and as one of the

costliest diseases, the impact of dementia cannot be underestimated.

Although research in this domain has made significant progress,

major challenges still lie ahead. There is a growing need of

biomarkers with the capacity to diagnose Alzheimer’s disease (AD) in

an early stage, predict prognosis for prodromal patients and ...

Alzheimer’s disease (AD) is progressive neurodegenerative disorder estimated to affect more than 150 million people by 2050. γ-Secretases (GSECs) are proteases which embedded in the membrane cut several substrates, including the amyloid precursor protein (APP). This cleavage process gained considerable scientific interest as more than 200 mutations in GSEC and around 20 in APP, cause early onset AD. We have recently found that AD-causing ...